HALO vs. INSM: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at HALO and INSM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | HALO | INSM |
|---|---|---|
| Company Name | Halozyme Therapeutics, Inc. | Insmed Incorporated |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Biotechnology |
| Market Capitalization | 8.56 billion USD | 28.77 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | March 16, 2004 | June 1, 2000 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of HALO and INSM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | HALO | INSM |
|---|---|---|
| 5-Day Price Return | 1.30% | 6.06% |
| 13-Week Price Return | 33.66% | 96.65% |
| 26-Week Price Return | 26.14% | 75.61% |
| 52-Week Price Return | 13.55% | 77.84% |
| Month-to-Date Return | 21.98% | 26.86% |
| Year-to-Date Return | 53.00% | 97.13% |
| 10-Day Avg. Volume | 2.08M | 2.25M |
| 3-Month Avg. Volume | 2.38M | 3.49M |
| 3-Month Volatility | 23.06% | 65.04% |
| Beta | 1.18 | 1.05 |
Profitability
Return on Equity (TTM)
HALO
136.63%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
HALO’s Return on Equity of 136.63% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
INSM
-195.37%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
INSM has a negative Return on Equity of -195.37%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
HALO
47.28%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 47.28% places HALO in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
INSM
-259.82%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
INSM has a negative Net Profit Margin of -259.82%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
HALO
57.92%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 57.92% places HALO in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
INSM
-252.41%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
INSM has a negative Operating Profit Margin of -252.41%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | HALO | INSM |
|---|---|---|
| Return on Equity (TTM) | 136.63% | -195.37% |
| Return on Assets (TTM) | 26.44% | -49.49% |
| Net Profit Margin (TTM) | 47.28% | -259.82% |
| Operating Profit Margin (TTM) | 57.92% | -252.41% |
| Gross Profit Margin (TTM) | 84.20% | 75.72% |
Financial Strength
Current Ratio (MRQ)
HALO
8.36
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
HALO’s Current Ratio of 8.36 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
INSM
6.68
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
INSM’s Current Ratio of 6.68 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
HALO
4.54
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 4.54, HALO operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
INSM
0.45
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
INSM’s Debt-to-Equity Ratio of 0.45 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
HALO
143.47
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
With an Interest Coverage Ratio of 143.47, HALO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Biotechnology industry. This stems from either robust earnings or a conservative debt load.
INSM
-27.79
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
INSM has a negative Interest Coverage Ratio of -27.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | HALO | INSM |
|---|---|---|
| Current Ratio (MRQ) | 8.36 | 6.68 |
| Quick Ratio (MRQ) | 6.44 | 6.13 |
| Debt-to-Equity Ratio (MRQ) | 4.54 | 0.45 |
| Interest Coverage Ratio (TTM) | 143.47 | -27.79 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
HALO
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HALO currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
INSM
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INSM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
HALO
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HALO has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
INSM
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INSM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | HALO | INSM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
HALO
14.64
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Biotechnology industry, HALO’s P/E Ratio of 14.64 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
INSM
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for INSM is currently unavailable.
Price-to-Sales Ratio (TTM)
HALO
6.92
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
HALO’s P/S Ratio of 6.92 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
INSM
68.25
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
INSM’s P/S Ratio of 68.25 is in the upper echelon for the Biotechnology industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
HALO
19.26
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
HALO’s P/B Ratio of 19.26 is in the upper tier for the Biotechnology industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
INSM
15.28
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
INSM’s P/B Ratio of 15.28 is in the upper tier for the Biotechnology industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | HALO | INSM |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 14.64 | -- |
| Price-to-Sales Ratio (TTM) | 6.92 | 68.25 |
| Price-to-Book Ratio (MRQ) | 19.26 | 15.28 |
| Price-to-Free Cash Flow Ratio (TTM) | 15.09 | -- |